Pursuing novel therapeutics targeting NASH with liver fibrosis

Madrigal is a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases. Our most advanced clinical candidate, resmetirom, has the potential to become the first medication approved for the treatment of patients with non-alcoholic steatohepatitis (NASH) with liver fibrosis.

NASH is a growing global health challenge. There are 22 million people living with NASH in the U.S. alone, and more than 8 million who have NASH with significant liver fibrosis.